BPC-157 Dosage for Healing: What Protocols Cite

BPC-157 is a synthetic pentadecapeptide studied in animal models for soft-tissue and gut repair. For healing applications, research protocols commonly cite 250–500 mcg per injection, once or twice daily, across a 4–12 week cycle. Human clinical evidence is limited, and BPC-157 is not FDA-approved. This guide reviews the cited dosing, the evidence behind it, safety, and legal status.

BPC-157 dosage for healing — at a glance

• Class: synthetic pentadecapeptide (research peptide)
• Commonly cited dose: 250–500 mcg per injection
• Frequency: once or twice daily
• Typical cited cycle: 4–12 weeks
• Routes discussed in research: subcutaneous and intramuscular (parenteral); oral forms are also marketed
• Best-studied for: tendon, ligament, muscle-to-bone, and gastrointestinal tissue repair — in animal models
• FDA status (June 2026): not approved; removed from the 503A Category 2 list in April 2026; under PCAC review (July 23–24, 2026)
• Anti-doping status: prohibited at all times under WADA Section S0

What dosage do BPC-157 healing protocols commonly cite?

Across community and clinician-shared protocols, BPC-157 for healing is most often described in the range of 250–500 mcg per injection, given once or twice daily, for a cycle of roughly 4–12 weeks. That equates to a commonly cited daily total of about 250 mcg to 1,000 mcg (1 mg). Some protocols cite weight-based figures in the neighborhood of a few micrograms per kilogram of body weight, but no standardized, regulator-endorsed human dose exists.

It is important to be precise about where these numbers come from. They are derived largely from preclinical animal studies and from practitioner experience — not from large, published, peer-reviewed human dose-finding trials. The peptide's developers reported early human work in inflammatory bowel disease, but those trials were never published in full detail in the peer-reviewed literature, leaving the human dose evidence thin (Sikiric et al., 2010, Curr Pharm Des).

Because BPC-157 is not FDA-approved, there is no official label, no approved indication, and no sanctioned dosing schedule. Any figure you see online is a research-protocol convention, not a prescription. Consult your healthcare provider before starting any peptide protocol.

How does BPC-157 work in the research?

BPC-157 is a 15-amino-acid sequence originally identified as a fragment derived from a protein found in human gastric juice. In animal and cell models, two mechanisms recur most often in the literature.

First, angiogenesis — the formation of new blood vessels. In a 2017 study, BPC-157 increased blood-vessel density in chick-embryo and cell-culture assays and accelerated blood-flow recovery in rats with hind-limb ischemia. The effect was associated with increased expression and internalization of VEGFR2 and downstream activation of the VEGFR2–Akt–eNOS signaling pathway (Hsieh et al., 2017, J Mol Med).

Second, fibroblast migration and survival. In a tendon-healing study, BPC-157 did not directly increase fibroblast proliferation but significantly improved cell survival under oxidative (H₂O₂) stress and increased fibroblast migration in a dose-dependent manner, through activation of the FAK–paxillin signaling cascade (Chang et al., 2011, J Appl Physiol).

These mechanisms — better blood supply and more mobile, more resilient repair cells — are the biological rationale researchers give for the peptide's observed effects on connective tissue. They are well characterized in animals; how directly they translate to humans remains unestablished.

What is BPC-157 best studied for in healing?

The strongest preclinical signals are in connective-tissue and gastrointestinal repair. Clearly labeling the evidence level matters here: nearly all of it is animal-model data.

• Tendon-to-bone healing. In a rat Achilles-detachment model, BPC-157 improved healing functionally (Achilles functional index), biomechanically (load-to-failure, stiffness, elasticity modulus), and on histology, with better-organized collagen and more type I collagen than controls (Krivic et al., 2006, J Orthop Res).
• Tendon-cell biology. The 2011 fibroblast work above provides a cellular mechanism for accelerated tendon repair (Chang et al., 2011, J Appl Physiol).
• Gastrointestinal protection. In a rat gastric-ulcer model, intramuscular BPC-157 (reported around 800 ng/kg) produced significantly smaller lesions and outperformed famotidine across several ulcer models, with inhibition rates of roughly 45–66% depending on the model (Xue et al., 2004, World J Gastroenterol).

Research in animal models suggests BPC-157 may support tendon, ligament, muscle, and gut tissue repair. That is a categorically different statement from saying it heals an injury in a person. Human trials adequate to confirm efficacy and safety have not been completed (Sikiric et al., 2010, Curr Pharm Des).

For a fuller mechanism and indication breakdown, see our BPC-157 complete guide, and for how it is often paired with another repair peptide, our BPC-157 vs. TB-500 comparison.

How do research protocols structure BPC-157 dosing for healing?

The dosing conventions you will encounter typically vary along four parameters. The table below summarizes how protocols commonly frame each — it describes what the literature and practitioner protocols cite, not a recommendation to dose yourself.

A few points of nuance. Localized (near-injury) injection is sometimes described for tendon and joint applications, but the comparative human evidence for site-specific versus systemic dosing is not established. Oral BPC-157 is marketed and is supported by some GI animal data, yet oral bioavailability for systemic, connective-tissue targets is uncertain. And "more is better" is not supported — the animal dose-response curves are not linear, and higher doses have not been shown to produce proportionally better outcomes.

Because none of these parameters is regulator-validated for humans, the right structure for any individual is a clinical decision. Consult your healthcare provider before starting any peptide protocol. For background on injectable peptide handling generally, see our peptide injection basics.

How long do protocols say BPC-157 takes to work?

In animal studies, repair-relevant changes are reported within days to weeks. In the Krivic Achilles model, measurable functional and biomechanical improvement appeared across the first three weeks after detachment (Krivic et al., 2006, J Orthop Res). Community protocols commonly describe a 4–12 week window, framed around the time connective tissue needs to remodel.

These timelines come from preclinical work and self-reported experience, not controlled human outcome trials, so individual response is unknown and unpredictable. Anyone using a fixed "expect results by week X" framing is extrapolating beyond the published human data. Discuss realistic expectations, and how progress should be tracked, with a healthcare provider.

What are the side effects and safety considerations of BPC-157?

Honest answer first: human safety data are limited. The widely repeated claim that BPC-157 has "no side effects" originates largely from the peptide's original proponents and from animal toxicology, not from large independent human trials. Independent reviewers have characterized the human evidence base as scant and of low quality (Sikiric et al., 2010, Curr Pharm Des).

Key safety considerations cited in the literature and by regulators:

• Unknown long-term human risk. The FDA's stated concerns when restricting BPC-157 for compounding included potential immune reactions, manufacturing impurities, and a lack of human safety data (FDA, 503A bulk drug substances evaluation, 2023).
• Angiogenic activity is double-edged. Because BPC-157 promotes new blood-vessel growth via VEGFR2 signaling (Hsieh et al., 2017, J Mol Med), there is a theoretical concern about its use in anyone with an active or suspected malignancy, where new vessel formation can be undesirable. This is a hypothesis-level concern, but a reason to involve a physician.
• Product-quality risk. Research-grade and gray-market vials carry real risks of contamination, incorrect concentration, or mislabeling — independent of the peptide itself.

Because safety in humans is not established, BPC-157 should not be self-administered casually. Consult your healthcare provider before starting any peptide protocol, and disclose all medications and conditions, particularly any cancer history.

Is BPC-157 legal? FDA and sourcing status in 2026

BPC-157 is not FDA-approved for any use. Its compounding status changed meaningfully in 2026.

• 2023: The FDA placed BPC-157 in Category 2 of its 503A bulk-drug-substances evaluation, the bin for substances it determined should not be used in compounding pending more data (FDA, 2023).
• April 2026: The FDA removed BPC-157 from the Category 2 list. Per the agency context, this removal was largely procedural — tied to withdrawn nominations — and does not by itself authorize compounding [VERIFY: exact April 2026 FDA removal date, reported as ~April 22, 2026].
• July 23–24, 2026: The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review BPC-157 (alongside several other peptides) to advise whether it should be added to the 503A positive bulks list.

As of June 2026, BPC-157 sits in a transitional state: no longer explicitly banned under Category 2, but not yet on an approved positive bulks list. Both 503A and 503B compounding pathways remain restricted from using bulk BPC-157 pending final FDA rulemaking [VERIFY: post-PCAC 503A/503B status after July 2026 hearing].

Separately, for athletes, BPC-157 is prohibited at all times — in and out of competition — under Section S0 (non-approved substances) of the WADA Prohibited List, with no Therapeutic Use Exemption available (WADA 2026 Prohibited List; USADA).

Legal status varies by jurisdiction; consult a lawyer for binding advice. For where this fits in the broader repair-peptide landscape, see our peptides for healing overview.

Frequently asked questions

Q: What is the most commonly cited BPC-157 dosage for healing? A: Research-oriented protocols most often cite 250–500 mcg per injection, given once or twice daily, for a 4–12 week cycle — a daily total of roughly 250 mcg to 1 mg. These figures come from animal studies and practitioner experience, not from published human dose-finding trials, and BPC-157 has no FDA-approved dose. Treat any number you see as a research convention rather than a prescription, and personalize any protocol with a licensed healthcare provider.

Q: How is BPC-157 dosing calculated by body weight? A: Some protocols frame BPC-157 in micrograms per kilogram, but there is no validated human weight-based standard. Much of the animal data uses dosing in nanograms-to-micrograms per kilogram — for example, an anti-ulcer rat study used roughly 800 ng/kg intramuscularly (Xue et al., 2004, World J Gastroenterol). Animal dosing does not translate directly to humans. A healthcare provider should determine any dosing approach for an individual.

Q: Is subcutaneous or intramuscular injection better for healing? A: Both routes appear in BPC-157 research and protocols, and some practitioners inject near the injury site for tendon or joint goals. There is no robust human head-to-head evidence establishing one route as superior for healing outcomes. Animal studies have used intramuscular and other parenteral routes. Injection technique, sterility, and route should be guided by a healthcare provider, not self-determined.

Q: How long does BPC-157 take to work for tendon healing? A: In animal models, functional and biomechanical improvement in tendon repair was observed across the first few weeks (Krivic et al., 2006, J Orthop Res). Community protocols often describe a 4–12 week window. These timelines are extrapolated from preclinical data and self-reports, not controlled human outcome trials, so individual results are unpredictable. Discuss realistic expectations and progress tracking with a provider.

Q: Does a higher BPC-157 dose heal faster? A: There is no evidence that exceeding commonly cited doses produces proportionally faster or better healing in humans. Animal dose-response data are not linear, and BPC-157 is not FDA-approved, so no efficacy ceiling has been established in people. Higher doses also raise exposure to unknown long-term risks. Dose decisions should be made with a healthcare provider, not escalated independently.

Q: Is BPC-157 legal to buy in 2026? A: BPC-157 is not FDA-approved. It was removed from the FDA's 503A Category 2 list in April 2026, but that removal does not authorize compounding, and both 503A and 503B pathways remain restricted pending final rulemaking; the PCAC is reviewing it July 23–24, 2026. It is sold as a "research chemical," and it is banned in sport under WADA Section S0. Legal status varies by jurisdiction; consult a lawyer.

Q: Is BPC-157 safe? A: Human safety data are limited. Claims of "no side effects" come largely from the peptide's original proponents and animal data, and independent reviewers describe the human evidence as scant (Sikiric et al., 2010, Curr Pharm Des). The FDA has cited concerns about immune reactions, impurities, and missing human safety data. Its angiogenic activity also raises a theoretical caution in anyone with cancer. Consult your healthcare provider before considering use.

References

1. Chang C-H, Tsai W-C, Lin M-S, Hsu Y-H, Pang J-HS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID: 21030672. DOI: 10.1152/japplphysiol.00945.2010.
2. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982–989. PMID: 16583442. DOI: 10.1002/jor.20096.
3. Hsieh M-J, Liu H-T, Wang C-N, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. PMID: 27847966. DOI: 10.1007/s00109-016-1488-y.
4. Xue X-C, Wu Y-J, Gao M-T, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032–1036. PMID: 15052688. DOI: 10.3748/wjg.v10.i7.1032.
5. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5–6):214–221. PMID: 17186181. DOI: 10.1007/s10787-006-1531-7.
6. U.S. Food and Drug Administration. List of bulk drug substances for which FDA has evaluated nominations for use in compounding under section 503A (interim policy; Category 2 placement of BPC-157, 2023; status updated 2026). FDA.gov human drug compounding. [VERIFY: exact current FDA list URL and post-April-2026 entry status].
7. World Anti-Doping Agency. The 2026 Prohibited List (BPC-157 prohibited under Section S0, non-approved substances). WADA Prohibited List; see also USADA, "BPC-157: Experimental Peptide Creates Risk for Athletes," USADA.org.